Solomon BJ, Shaw A, Ignatius Ou S-H, et al. Phase 2 Study of Lorlatinib in Patients with Advanced ALK/ROS1 Non-Small-Cell Lung Cancer. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 05.06.
Nivolumab plus ipilimumab versus sunitinib bij gevorderd RCC: extended follow-up CheckMate 214
okt 2019 | Uro-oncologie